Theratechnologies Inc
TSX:TH
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.58
3.05
|
Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one TH stock under the Base Case scenario is 7.66 CAD. Compared to the current market price of 1.74 CAD, Theratechnologies Inc is Undervalued by 77%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Theratechnologies Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for TH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Theratechnologies Inc
Balance Sheet Decomposition
Theratechnologies Inc
Current Assets | 57.2m |
Cash & Short-Term Investments | 38.9m |
Receivables | 10.7m |
Other Current Assets | 7.7m |
Non-Current Assets | 12.5m |
PP&E | 788k |
Intangibles | 11.4m |
Other Non-Current Assets | 259k |
Current Liabilities | 52.9m |
Accounts Payable | 23.8m |
Other Current Liabilities | 29.1m |
Non-Current Liabilities | 36.5m |
Long-Term Debt | 36.5m |
Other Non-Current Liabilities | 18k |
Earnings Waterfall
Theratechnologies Inc
Revenue
|
84.3m
USD
|
Cost of Revenue
|
-19.4m
USD
|
Gross Profit
|
64.9m
USD
|
Operating Expenses
|
-55.9m
USD
|
Operating Income
|
9m
USD
|
Other Expenses
|
-12.2m
USD
|
Net Income
|
-3.2m
USD
|
Free Cash Flow Analysis
Theratechnologies Inc
USD | |
Free Cash Flow | USD |
In Q3 2024, Theratechnologies reported strong financial results, with net sales rising 8.4% to $22.6 million. EGRIFTA SV sales notably surged by 27% year-over-year to $16.7 million, driven by robust patient enrollment. However, Trogarzo sales fell to $5.9 million due to competitive pressures. Adjusted EBITDA reached $7.2 million, prompting a revenue guidance revision to $83-$85 million and EBITDA guidance increased to $17-$19 million for 2024. Despite expected supply constraints impacting Q4 sales, strategic cost management and a strong cash position of $39 million positions the company for sustained growth.
What is Earnings Call?
TH Profitability Score
Profitability Due Diligence
Theratechnologies Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Theratechnologies Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
TH Solvency Score
Solvency Due Diligence
Theratechnologies Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Theratechnologies Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TH Price Targets Summary
Theratechnologies Inc
According to Wall Street analysts, the average 1-year price target for TH is 8.16 CAD with a low forecast of 8.08 CAD and a high forecast of 8.4 CAD.
Dividends
Current shareholder yield for TH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).
Contact
IPO
Employees
Officers
The intrinsic value of one TH stock under the Base Case scenario is 7.66 CAD.
Compared to the current market price of 1.74 CAD, Theratechnologies Inc is Undervalued by 77%.